Abstract:OBJECTIVE:To develop monoclonal antibodies that can specifically recognize human von Willebrand factor (VWF) propeptide (VWFpp) in plasma, and establish a rapid and reliable method for the detection of VWFpp antigen in plasma by using the double-antibody sandwich ELISA with the obtained anti-VWFpp monoclonal antibody.METHODS:The recombinant human VWFpp (D1 and D2 regions) protein expressed in eukaryotic cells was used as immunogen to immunize BALB/c mice with routine method, so as to obtain clones of fusion cells. After screening and identification, hybridoma cell lines secreting monoclonal antibodies against VWFpp were selected, and then double-antibody sandwich ELISA assay was used to construct VWFpp antigen detection kit for the determination of VWFpp in human plasma. The levels of VWFpp antigen in plasma of 12 leukemia patients who underwent bone marrow transplantation were dynamically detected.RESULTS:Two hybridoma cell lines that can be subcultured continuously and secrete monoclonal antibodies against VWFpp were obtained and named SZ175 and SZ176 respectively. Identified by ELISA and Western blot, the antibodies could both specifically recognize VWFpp but couldn't recognize mature VWF (without propeptide). Based on the principle of double-antibody sandwich ELISA, monoclonal antibodies SZ175 and SZ176 were successfully made into a kit for detecting VWFpp antigen. The plasma VWFpp levels of leukemia patients before and after bone marrow transplantation were dynamically detected. The results showed that the plasma VWFpp levels of the patients after transplantation were significantly higher than those before transplantation.CONCLUSION:Two monoclonal antibodies against VWFpp were successfully prepared, and a double-antibody sandwich ELISA detection kit for VWFpp antigen was constructed, which provides a powerful tool for further study on the biological function of VWFpp, the clinical diagnosis and classification of von Willebrand disease (VWD), and the prognostic monitoring of endothelial injury-related diseases.

Development and Clinical Application of Diagnostic Tests for Von Willebrand Disease

The Comparison Study of Four Kinds of Tests for Diagnosis of Von Willebrand Disease

The New Diagnostic Test of Vwd2n

Development Of An Elisa Method For Testing Vwf Ristocetin Cofactor Activity With Improved Sensitivity And Reliability In The Diagnosis Of Von Willebrand Disease

Molecular diagosis of von Willebrand disease

Application of von Willebrand Factor Antigen test in the Differential Diagnosis of von Willebrand Disease and Hemophilia A

[Application of Collagen-Binding Assay for Von Willebrand Disease].

The Phenotypic and Genotypic Diagnosis of Three Chinese Patients with Von Willebrand Disease

Does the VWF:CB Assay Help to Diagnose von Willebrand Factor Deficiency in Patients With a Bleeding Disorder of Unknown Cause?

Von Willebrand Factor (VWF) multiplex activity assay differentiation of type 1 von Willebrand Disease (VWD) and variant VWD

Development of a novel flow cytometric immunobead array to quantify VWF: Ag and VWF: GPIbR and its application in acute myocardial infarction.

Establishment and Clinical Application of Flow Cytometric Immunobead Array in Detecting Plasma Von Willebrand Factor Antigen

[Clinical Studies of 162 Patients with Von Willebrand Disease].

Diagnosis and management of von Willebrand disease in China.

[Phenotype and Genotype Analysis of Three Chinese Pedigrees with Von Willebrand Disease].

Prevalence and characterization of anti-VWF antibodies in a population of patients with type 3 VWD

Establishment of variables-specific reference ranges of von Willebrand factor antigen and activity

Von Willebrand factor in diagnostics and treatment of cardiovascular disease: Recent advances and prospects

Diagnosis and treatment of von Willebrand disease in 2024 and beyond

[Preparation and Application of Monoclonal Antibody Against Human Von Willebrand Factor Propeptide].

Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.